Peyman H, Esterberg E, Obermuller D, Bartsch R. Bone evaluation study-2: update on the epidemiology of osteoporosis in Germany. Dtsch Arztebl Int. 2024 Apr 9;19(1):26. doi: 10.1007/s11657-024-01380-9
Zografos L, Wolin D, Andrews E, Calingaert B, Balabanova Y, Horvat-Brocker A, Tarenz C, Suzart-Woischnik K. Evaluating patient and physician knowledge of risks and safe use of rivaroxaban: a survey across four countries. Expert Opin Drug Saf. 2022 Mar;21(3):435-46. doi: 10.1080/14740338.2022.1998451
Lavonas EJ, Fries JF, Furst DE, Rothman KJ, Stergachis A, Vaida AJ, Zelterman D, Reynolds KM, Green JL, Dart RC. Comparative risks of non-prescription analgesics: a structured topic review and research priorities. Expert Opin Drug Saf. 2012 Jan 1;11(1):33-44.
Akashi-Ronquest N. The impact of biological preferences on parental investments in children and step-children. Rev Econ Househ. 2009 Mar 1;7(1):59-81.
Van Houtven CH, Wilson MR, Clipp EC. Informal care intensity and caregiver drug utilization. Rev Econ Househ. 2005;3(4):415-33.
Finkelstein EA, Kosa KM. Use of incentives to motivate healthy behaviors among employees. Gender issues. 2003 Jun;21(3):50-9. doi: 10.1007/s12147-003-0005-0